Implantable Cardioverter Defibrillator (ICD) - (Effective Date - 2026-06-15) 7.01.06
Effective date
Jun 15, 2026
Identified
Jun 20, 2026
Summary
Excellus policy 7.01.06 Implantable Cardioverter Defibrillator (ICD) has a current effective date of June 15, 2026. The 02/19/26 off-cycle update changed criteria for post cardiac arrest, structural heart disease with sustained VT, syncope of undetermined origin with a positive EP study, and unexplained syncope with sustained VT and normal LV function, and it added separate primary prevention and secondary prevention sections. The policy considers ICDs not medically necessary for incessant VT or VF, for VT or VF due to a reversible cause, and for ablation candidates with no structural heart disease.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.
01Already effective June 15, 2026: Billing team: ICD claims need documentation that the patient meets a primary prevention or secondary prevention indication in Policy Statements I through VII, such as LVEF of 35% or less after at least three months of optimal medical therapy for ischemic cardiomyopathy.
02Policy Guideline I says there should first be a consultation with an electrophysiologist before an ICD is implanted, so document that consultation.
03Subcutaneous ICD claims need documentation of a contraindication to a transvenous ICD, no indication for anti-bradycardia pacing, and no ventricular arrhythmias known or anticipated to respond to anti-tachycardia pacing.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.